ATE141511T1 - Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden. - Google Patents

Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden.

Info

Publication number
ATE141511T1
ATE141511T1 AT92908524T AT92908524T ATE141511T1 AT E141511 T1 ATE141511 T1 AT E141511T1 AT 92908524 T AT92908524 T AT 92908524T AT 92908524 T AT92908524 T AT 92908524T AT E141511 T1 ATE141511 T1 AT E141511T1
Authority
AT
Austria
Prior art keywords
bacteriocin
helicobacter pylori
production
pct
medicinal product
Prior art date
Application number
AT92908524T
Other languages
English (en)
Inventor
Peter John Edwards
Kim Morwood
Original Assignee
Applied Microbiology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919108129A external-priority patent/GB9108129D0/en
Priority claimed from GB919114149A external-priority patent/GB9114149D0/en
Application filed by Applied Microbiology Inc filed Critical Applied Microbiology Inc
Application granted granted Critical
Publication of ATE141511T1 publication Critical patent/ATE141511T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT92908524T 1991-04-15 1992-04-10 Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden. ATE141511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919108129A GB9108129D0 (en) 1991-04-15 1991-04-15 Pharmaceutical composition
GB919114149A GB9114149D0 (en) 1991-07-01 1991-07-01 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE141511T1 true ATE141511T1 (de) 1996-09-15

Family

ID=26298737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92908524T ATE141511T1 (de) 1991-04-15 1992-04-10 Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden.

Country Status (10)

Country Link
US (1) US5559096A (de)
EP (1) EP0589893B1 (de)
JP (1) JP3334879B2 (de)
AT (1) ATE141511T1 (de)
AU (1) AU665188B2 (de)
CA (1) CA2108455C (de)
DE (1) DE69213010T2 (de)
DK (1) DK0589893T3 (de)
IE (1) IE921193A1 (de)
WO (1) WO1992018143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139883A1 (de) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Verfahren zur herstellung bioadhaesiver arzneimittel
WO1993011783A1 (en) * 1991-12-09 1993-06-24 Magainin Pharmaceuticals Inc. Composition and treatment with biologically active peptides and chelating agents
EP0666759A1 (de) * 1992-10-29 1995-08-16 DENECKE, Rainer Präparat zur therapie und insbesondere prophylaxe von erkrankungen des verdauungstraktes
DE4307352A1 (de) * 1992-10-29 1994-05-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und insbesondere Prophylaxe von Erkrankungen des Verdauungstraktes
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US6521596B1 (en) * 1994-04-20 2003-02-18 The Uab Research Foundation Lanthionine antibiotic compositions and method
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
JPH08133971A (ja) * 1994-09-16 1996-05-28 Toyama Chem Co Ltd 抗ヘリコバクター剤
US6379651B1 (en) * 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5804549A (en) * 1996-01-05 1998-09-08 Ambi Inc. Compositions with activity against helicobacter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
KR100375342B1 (ko) * 2000-02-08 2003-03-08 주식회사 풀 무 원 위장 질환 개선을 위한 천연 항균물질 조성물
EP1148064A1 (de) * 2000-04-17 2001-10-24 Vrije Universiteit Brussel Ein aus Lactobacillus johnsonii faecium stammendes gegen Helicobacter pylori wirksames bakteriocin
US6342385B1 (en) 2000-07-28 2002-01-29 The Uab Research Foundation Mutacin I biosynthesis genes and proteins
CN1226037C (zh) * 2001-05-03 2005-11-09 法米基股份公司 硫糖铝在制备治疗宫颈糜烂药物上的用途
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
CA2548915C (en) * 2003-12-31 2012-10-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Phoenix Labs Unlimited Company Effervescent oral opiate dosage form
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
AR073014A1 (es) * 2008-08-12 2010-10-06 Dsm Ip Assets Bv Composiciones liquidas de nisina
WO2010038237A2 (en) 2008-09-22 2010-04-08 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
AR080194A1 (es) 2010-02-17 2012-03-21 Dsm Ip Assets Bv Composiciones antimicrobianas liquidas
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486448T2 (de) * 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
AT391959B (de) 1988-06-03 1990-12-27 Dau Ges M B H & Co Kg Koppler zur potentialgetrennten uebertragung eines zweiwertigen signales mittels eines impulstransformators
US5304540A (en) * 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
US5334582A (en) * 1988-06-22 1994-08-02 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection

Also Published As

Publication number Publication date
AU1581192A (en) 1992-11-17
US5559096A (en) 1996-09-24
DE69213010D1 (de) 1996-09-26
EP0589893A1 (de) 1994-04-06
WO1992018143A1 (en) 1992-10-29
JP3334879B2 (ja) 2002-10-15
EP0589893B1 (de) 1996-08-21
JPH07503451A (ja) 1995-04-13
AU665188B2 (en) 1995-12-21
DK0589893T3 (da) 1996-09-09
IE921193A1 (en) 1992-10-21
CA2108455C (en) 1999-01-19
CA2108455A1 (en) 1992-10-16
DE69213010T2 (de) 1997-01-23

Similar Documents

Publication Publication Date Title
ATE141511T1 (de) Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden.
NO960067D0 (no) Nytt farmasöytisk preparat
ES2154336T3 (es) Producto para el cuidado de la piel.
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
BG105275A (en) Tan-1057 derivatives
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
ATE143947T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69230790D1 (de) Arzneimittel zur Behandlung von durch Babesia verursachten Protozoeninfektionen
SI0863752T1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
ATE28566T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.
GB9216859D0 (en) Medicaments
ATE143946T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
HUT57040A (en) Process for producing pharmaceutical compositions comprising 2-brackets open 4-(4-chlorophenyl)-cyclohexyl brackets closed-3-hydroxy-1,4-naphthoquinone suitable for treating toxoplasmosis
ATE107504T1 (de) Arzneimittel zur behandlung von kryptosporidiose.
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
NZ268476A (en) 14-substituted marcfortines, preparation and pharmaceutical compositions thereof
DE59403326D1 (de) Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE306273T1 (de) Verwendung von tiludronsäure beim geflügel zur herstellung eines arzneimittels zur prophylaxe und behandlung von osteoporose
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee